The present invention relates to novel heterocyclic antagonists of Formula (I)
and pharmaceutical compositions comprising said antagonists of the corticotropin
releasing factor receptor ("CRF receptor")
##STR1##
useful for the treatment of depression, anxiety, affective disorders, feeding
disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory
disorders, drug or alcohol withdrawal symptoms and other conditions the treatment
of which can be effected by the antagonism of the CRF-1 receptor.
